PMID- 22817122
OWN - NLM
STAT- MEDLINE
DCOM- 20130531
LR  - 20221207
IS  - 1744-9987 (Electronic)
IS  - 1744-9979 (Linking)
VI  - 16
IP  - 4
DP  - 2012 Aug
TI  - Randomized crossover study of the efficacy and safety of sevelamer hydrochloride 
      and lanthanum carbonate in Japanese patients undergoing hemodialysis.
PG  - 341-9
LID - 10.1111/j.1744-9987.2012.01071.x [doi]
AB  - Insufficient control of serum calcium and phosphate levels in patients undergoing 
      hemodialysis is associated with increased mortality. As commonly used 
      calcium-containing phosphate binders can cause arterial calcification, newly 
      developed calcium-free phosphate binders, such as sevelamer hydrochloride (SH) 
      and lanthanum carbonate (LC), have received much attention. We assessed the 
      efficacy and safety of SH and LC treatment in Japanese patients undergoing 
      hemodialysis in a prospective randomized open blinded endpoint (PROBE) crossover 
      study. Forty-two patients were randomized to receive SH or LC for 13 weeks, with 
      the dosages adjusted every 2 weeks, followed by treatment with the other drug for 
      another 13 weeks. The average daily doses of SH and LC were 2971 +/- 1464 mg and 
      945 +/- 449 mg, respectively. The mean dosage ratio of SH to LC was 3.05, which was 
      maintained throughout the treatment period. SH and LC were similarly effective at 
      controlling serum calcium and phosphate levels in the majority of patients 
      (78-93%). A few serious adverse events (AEs) involving the biliary system 
      occurred during the LC treatment period, but they were not considered to be 
      treatment-induced. Although the incidence of constipation, the most common 
      treatment-related AE, was higher during the SH period (27% vs. 5%; P < 0.05), no 
      difference was observed in total treatment-related AEs. This study demonstrates 
      that SH and LC are comparable treatments for controlling serum phosphate and 
      calcium levels, and that both compounds are safe and well-tolerated in Japanese 
      patients undergoing hemodialysis.
CI  - (c) 2012 The Authors. Therapeutic Apheresis and Dialysis (c) 2012 International 
      Society for Apheresis.
FAU - Kasai, Satoshi
AU  - Kasai S
AD  - Department of Internal Medicine, Japanese Red Cross Ishinomaki Hospital, 
      Ishinomaki, Japan. skasai@ishinomaki.jrc.or.jp
FAU - Sato, Kazuto
AU  - Sato K
FAU - Murata, Yaeko
AU  - Murata Y
FAU - Kinoshita, Yasumichi
AU  - Kinoshita Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20120511
PL  - Australia
TA  - Ther Apher Dial
JT  - Therapeutic apheresis and dialysis : official peer-reviewed journal of the 
      International Society for Apheresis, the Japanese Society for Apheresis, the 
      Japanese Society for Dialysis Therapy
JID - 101181252
RN  - 0 (Chelating Agents)
RN  - 0 (Phosphates)
RN  - 0 (Polyamines)
RN  - 490D9F069T (lanthanum carbonate)
RN  - 6I3K30563S (Lanthanum)
RN  - 9YCX42I8IU (Sevelamer)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Asian People
MH  - Calcium/blood
MH  - Chelating Agents/adverse effects/*therapeutic use
MH  - Constipation/chemically induced
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Hyperphosphatemia/*drug therapy
MH  - Lanthanum/adverse effects/*therapeutic use
MH  - Male
MH  - Phosphates/blood
MH  - Polyamines/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Renal Dialysis/*adverse effects
MH  - Sevelamer
MH  - Treatment Outcome
EDAT- 2012/07/24 06:00
MHDA- 2013/06/01 06:00
CRDT- 2012/07/24 06:00
PHST- 2012/07/24 06:00 [entrez]
PHST- 2012/07/24 06:00 [pubmed]
PHST- 2013/06/01 06:00 [medline]
AID - 10.1111/j.1744-9987.2012.01071.x [doi]
PST - ppublish
SO  - Ther Apher Dial. 2012 Aug;16(4):341-9. doi: 10.1111/j.1744-9987.2012.01071.x. 
      Epub 2012 May 11.